Citius Pharmaceuticals Inc Stock Price, News & Analysis

Citius Pharmaceuticals (Nasdaq: CTXR) will present at the 12th annual LD Micro LD 500 conference on September 1 at 11:00 AM ET. Chairman Leonard Mazur will provide updates on the company's product developments, including treatments for acute respiratory distress syndrome related to COVID-19. This virtual event, accessible to all, runs from September 1 to September 4. This marks a significant opportunity for investors to gain insights into Citius’s strategic direction and product pipeline.

Citius Pharmaceuticals (CTXR) has expanded its intellectual property related to Mino-Wrap, a novel product aimed at reducing post-mastectomy infections involving tissue expanders. The USPTO has granted patent 10,434,221 B2, enhancing the design and application of Mino-Wrap under a global license agreement with MD Anderson Cancer Center. Approximately 100,000 U.S. patients undergo breast reconstruction annually, with infection rates for tissue expanders ranging from 2.5% to 24%. Mino-Wrap aims to significantly decrease this infection risk, potentially improving patient outcomes and reducing hospitalization.

Citius Pharmaceuticals (Nasdaq: CTXR) announced its participation in the MoneyShow Las Vegas Virtual Expo from August 18 to 20, 2020. The company's presentation is scheduled for August 19 at 4:50 PM ET, led by Chairman Leonard Mazur. Key topics include the recent $9.6 million public stock offering and a briefing to the FDA regarding Mino-Wrap, aimed at reducing post-operative infections. Investors can register for the event to access the live webcast.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced the successful closing of its public offering, selling 9,159,524 common shares at $1.05 each, including an option for the underwriter to purchase an additional 1,194,720 shares. The offering generated approximately $9.6 million in gross proceeds, which will be used for general corporate purposes, notably for clinical trials related to Mino-Lok and Halo-Lido, among other product development initiatives. This move reflects Citius's strategy to enhance its critical care product portfolio.

Citius Pharmaceuticals (Nasdaq: CTXR) announced an increased public offering of 7,964,804 shares at $1.05 per share, anticipated to close on August 10, 2020. The offering is projected to generate gross proceeds of approximately $8.4 million, which will fund general corporate purposes, including its Phase 3 clinical trial for Mino-Lok® and the development of Halo-Lido cream. H.C. Wainwright & Co. is the sole underwriter, with a 30-day option for an additional 1,194,720 shares.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has entered into an underwriting agreement with H.C. Wainwright & Co. for a public offering of 5,714,286 shares at $1.05 each, projected to close on or about August 10, 2020. This offering is expected to yield approximately $6.0 million before fees. A 30-day option allows the underwriter to purchase an additional 857,142 shares. Proceeds will support general corporate purposes, including clinical trials for Mino-Lok and Halo-Lido, and other development initiatives.

Citius Pharmaceuticals (NASDAQ: CTXR) has announced advancements in its product Mino-Wrap, aimed at reducing post-operative infections in breast reconstructive surgeries. The company has submitted a briefing package to the FDA, including pre-clinical data and a clinical development plan. Mino-Wrap is a gel-based wrap containing minocycline and rifampin, meant to protect tissue expanders from infections. With infection rates between 2.5% and 24%, Mino-Wrap aims to minimize complications that could delay cancer treatment. Citius is also collaborating with MD Anderson Cancer Center on this initiative.

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) has established the Citius ARDS Scientific Advisory Board to guide the development of its induced mesenchymal stem cells (iMSCs) for treating Acute Respiratory Distress Syndrome (ARDS), especially in COVID-19 patients. The board comprises experts like Dr. Michael A. Matthay, Dr. Mitchell M. Levy, and Dr. Lorraine B. Ware, all recognized leaders in critical care and clinical trials. CEO Myron Holubiak expressed confidence in their expertise to enhance clinical trial design and execution for iMSC therapy.

Citius Pharmaceuticals (Nasdaq: CTXR) announced its participation in the MoneyShow Accredited Investor Virtual Event from July 22-24, 2020. Chairman Leonard Mazur will provide updates on the company's developmental products during a live presentation scheduled for 10:40 AM ET on July 22. Attendees can interact with the company in real-time, and an archived webcast will be available post-event. Interested investors must register for the event at the provided link.